Duane H. Hamilton, Ph.D.

Duane H. Hamilton, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology


Dr. Hamilton is a Staff Scientist and Head of the Immunomodulation Group of the Center for Immuno-Oncology, NCI. This group focuses on the identification and characterization of tumor-specific neoepitopes and their use in combination therapies. This group is also involved in the genetic modification to tumor cells to identify mechanisms of action of specific immunotherapeutic agents.

Dr. Hamilton received his Ph.D. in Immunology from the University of Saskatchewan, Canada. Dr. Hamilton's research interests include cellular immunotherapy; tumor immunology; cancer vaccines. The Immunomodulation Group is working to identify and characterize tumor-specific neoepitopes and their use in combination therapies. We are also involved in the genetic modification to tumor cells to identify mechanisms of action of specific immunotherapeutic agents. This group evaluates techniques to identify tumor antigens unique to a patient’s own tumor. It is this group's belief that vaccinating patients with neoepitopes uniquely expressed by their tumor will improve the breadth of anti-tumor immunity generated by the lab's vaccine platforms, and result in greater immunological control of tumor growth.

Areas of Expertise

Cancer Immunotherapy
CTL Epitopes


Selected Key Publications

Efficient tumor clearance and diversified immunity through neoepitope vaccines and combinatorial immunotherapy

Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH
Cancer Immunol Res. 7(8): 1359-1370, 2019. [ Journal Article ]

Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer

Hamilton DH, Griner LM, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M, Palena C.
Clin Cancer Res. 22: 6204-16, 2016. [ Journal Article ]

WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition

Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C.
Cancer Res. 74: 2510-2519, 2014. [ Journal Article ]

Immune targeting of tumor epithelial-mesenchymal transition via brachyury-based vaccines (Review)

Palena C, Hamilton DH.
Adv Cancer Res. 128: 69-93, 2015. [ Journal Article ]

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition

Palena C, Fernando RI, Hamilton DH.
OncoImmunol. 3: e27220, 2014. [ Journal Article ]


Maria Del Mar Gracia Hernandez
Visiting Fellow
Maria Del Mar Gracia Hernandez, PhD
Maria Del Mar Maldonado Montalban, PhD
Postdoctoral Fellow (CRTA)
Maria Del Mar Maldonado Montalban, Ph.D.
Loc H. Le
Scientist (Contr)
Loc H. Le, PhD